日报更新时间：
周报更新时间：04-11 03:39
今开价：160.92
最高价：162.74
成交量：623851.0
昨收价：161.4
最低价：159.21
最新价：162.28
中文名称：爵士制药
英文名称：Jazz Pharmaceuticals PLC
行业：医疗
简介：Jazz Pharmaceuticals Public Limited Company是一家公众有限责任公司，根据爱尔兰法律于2005年3月成立
电话：353-1-6347800
Jazz Pharmaceuticals是一家专业生物制药公司，主要在美国、欧洲及国际间从事各种医学所需之药品的参与、研发及销售。爵士制药公司产品包括： Xyrem——用于治疗患者发作性睡病-猝倒症/嗜睡症(EDS)用药； Erwinaze——用于治疗急性淋巴性白血病； Defitelio——用于造血干细胞移植(HSCT)后潜在的致命并发症-肝脏静脉阻塞性疾病(VOD)治疗及预防； Prialt——用于治疗剧烈慢性疼痛； FazaClo LD——精神分裂症用药； FazaClo HD tablets； Versacloz； JZP-110——用于治疗患者嗜睡症(EDS)——临床阶段； JZP-386——羟丁酸钠产品，改良式氘类似物，用于嗜睡症的治疗——临床阶段； Asparec——用于治疗急性淋巴性白血病(ALL)及大肠杆菌-天门冬醯胺过敏症——I期临床试验阶段； Defibrotide——用于治疗重度肝脏静脉阻塞性疾病(VOD)——临床试验阶段； Leukotac——一种anti-CD25单克隆抗体，用于治疗类固醇无效性急性移植物抗宿主反应——III期临床试验阶段。爵士制药Jazz Pharmaceuticals(JAZZ)历史沿革： 2003年，Jazz Pharmaceuticals成立； 2005年，爵士制药公司收购Orphan Medical和其产品——Xyrem®； 2007年，Jazz Pharmaceuticals发布Luvox CR®； 2011年9月19日，爵士制药同意Azur Pharma合并，交易于2012年完成，为公司带来了新产品——Prialt®； 2012年，Jazz Pharmaceuticals以6.5亿美金收购EUSA Pharma，包括其产品——Erwinaze®/Erwinase®； 2013年，爵士制药与Concert Pharmaceuticals(NASDAQ:CNCE)协议开发JZP-386； 2014年，Jazz Pharmaceuticals从Aerial BioPharma手里收购JZP-110开发权； 2014年，爵士制药以10亿美金收购Gentium公司，包括其产品Defitelio® (defibrotide)； 2014年，Jazz Pharmaceuticals从Sigma-Tau Pharma手里收购Defitelio® (defibrotide)在美国的专利权； 2015年，爵士制药开始JZP-110的III期临床试验； 2016年5月31日，生物制药公司Jazz宣布以15亿美元收购制药公司Celator，以获得其用于治疗急性髓性白血病的研究性药物，交易于同年7月份完成。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-08-14 | Miller (Michael Patrick) | Officer | Sell | 200 | 144.38 |
| 2017-08-13 | Treacy Paul | Officer | Sell | 1104 | 143.30 |
| 2017-08-13 | Treacy Paul | Officer | Sell | 200 | 143.41 |
| 2017-08-10 | Berns (Paul L) | Director | Sell | 3 | 144.13 |
| 2017-08-10 | O'Keefe (Kenneth W) | Director | Sell | 3 | 144.11 |
| 2017-08-10 | Sohn (Catherine Angell) | Director | Sell | 3 | 144.22 |
| 2017-08-10 | Sohn (Catherine Angell) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | Gray Peter | Director | Sell | 714 | 142.36 |
| 2017-08-10 | Enright (Patrick G) | Director | Sell | 3 | 144.13 |
| 2017-08-10 | Enright (Patrick G) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | Mcsharry Heather Ann | Director | Sell | 3 | 144.13 |
| 2017-08-10 | Mcsharry Heather Ann | Director | Sell | 714 | 142.36 |
| 2017-08-10 | Schnee (Elmar J) | Director | Sell | 3 | 144.20 |
| 2017-08-10 | Schnee (Elmar J) | Director | Sell | 1194 | 142.36 |
| 2017-08-10 | Berns (Paul L) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | Winningham (Rick E) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | O'Keefe (Kenneth W) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | Riedel (Norbert G) | Director | Sell | 659 | 142.36 |
| 2017-08-10 | Winningham (Rick E) | Director | Sell | 3 | 144.22 |
| 2017-08-10 | Gray Peter | Director | Sell | 3 | 144.22 |
| 2017-08-10 | Riedel (Norbert G) | Director | Sell | 3 | 144.13 |
| 2017-08-10 | Schnee (Elmar J) | Director | Sell | 2 | 144.13 |
| 2017-08-09 | Gray Peter | Director | Buy | 1365 | -- |
| 2017-08-09 | Winningham (Rick E) | Director | Buy | 1365 | -- |
| 2017-08-09 | Mcsharry Heather Ann | Director | Buy | 1365 | -- |
| 2017-08-09 | Schnee (Elmar J) | Director | Buy | 1365 | -- |
| 2017-08-09 | Sohn (Catherine Angell) | Director | Buy | 1365 | -- |
| 2017-08-09 | Enright (Patrick G) | Director | Buy | 1365 | -- |
| 2017-08-09 | Riedel (Norbert G) | Director | Buy | 1365 | -- |
| 2017-08-09 | Berns (Paul L) | Director | Buy | 1365 | -- |
| 第 页, 共 10 页 首页 上页 下页 末页 | |||||
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| HHG PLC | 688679 | 1.21% | -2609 | -0.38% | 2019-03-31 |
| BlackRock Fund Advisors | 1534127 | 2.71% | 1054 | 0.07% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 1574395 | 2.78% | -34065 | -2.12% | 2019-07-31 |
| Renaissance Technologies Corp | 1993101 | 3.49% | 842900 | 73.28% | 2019-03-31 |
| Fidelity Management and Research Company | 3297753 | 5.78% | -1179331 | -26.34% | 2019-03-31 |
| Fidelity Management & Research Company | 3288521 | 5.81% | -1474668 | -30.96% | 2019-07-31 |
| FMR Inc | 3413659 | 5.99% | -1177608 | -25.65% | 2019-03-31 |
| BlackRock Inc | 4064622 | 7.13% | -76094 | -1.84% | 2019-03-31 |
| Vanguard Group Inc | 5068898 | 8.89% | 24032 | 0.48% | 2019-03-31 |
| TIAA-CREF Investment Management LLC | 1539767 | 2.70% | 184878 | 13.65% | 2019-03-31 |
| State Street Corporation | 1470973 | 2.58% | 86114 | 6.22% | 2019-03-31 |
| Putnam Investment Management, LLC | 1418622 | 2.51% | -844294 | -37.31% | 2019-07-31 |
| Geode Capital Management, LLC | 715594 | 1.25% | -548466 | -43.39% | 2019-03-31 |
| AQR Capital Management LLC | 719623 | 1.26% | 216323 | 42.98% | 2019-03-31 |
| Fidelity International Ltd | 805409 | 1.41% | -36358 | -4.32% | 2019-03-31 |
| Teachers Advisors LLC | 907496 | 1.59% | 196047 | 27.56% | 2019-03-31 |
| LSV Asset Management | 1001650 | 1.76% | 237190 | 31.03% | 2019-03-31 |
| Putnam Investments LLC | 1282019 | 2.25% | -1797005 | -58.36% | 2019-03-31 |
| J.P. Morgan Investment Management, Inc. | 1276652 | 2.25% | 12586 | 1.00% | 2019-07-31 |
| Boston Partners Global Investors, Inc | 1305663 | 2.29% | -9708 | -0.74% | 2019-03-31 |
| Bank of New York Mellon Corp | 1445481 | 2.54% | -244904 | -14.49% | 2018-12-31 |
| Apg All Pensions Group | 1154508 | 2.03% | 735054 | 175.24% | 2018-12-31 |
| APG Asset Management | 1154508 | 2.03% | 735054 | 175.24% | 2018-12-31 |
| Westfield Capital Management Company, LP | 1143835 | 2.02% | 31100 | 2.79% | 2018-12-31 |
| Viking Global Investors LP | 916992 | 1.62% | -33289 | -3.50% | 2018-12-31 |
| JPMorgan Chase & Co | 1912173 | 3.35% | 106291 | 5.89% | 2018-09-30 |
| Partner Fund Management LP | 958025 | 1.59% | -280881 | -22.67% | 2018-09-30 |
| Senator Investment Group LP | 1025000 | 1.70% | -5000 | -0.49% | 2018-09-30 |
| Orbimed Advisors, LLC | 1040100 | 1.72% | -- | -- | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 1699428 | 2.82% | 639759 | 60.37% | 2018-06-30 |
| Putnam Investment Management,LLC | 4866192 | 8.07% | -2315684 | -32.24% | 2018-06-30 |
| Waddell & Reed Investment Management Co | 1002568 | 1.66% | -186909 | -15.71% | 2018-06-30 |
| Waddell & Reed Financial Inc | 1002568 | 1.66% | -186909 | -15.71% | 2018-06-30 |
| J.P. Morgan Investment Management Inc | 1310285 | 2.17% | 192210 | 17.19% | 2018-06-30 |
| State Street Corp | 1211983 | 2.01% | 528933 | 77.44% | 2018-06-30 |
| Robeco Investment Management, Inc. | 1089656 | 1.81% | 18821 | 1.76% | 2018-06-30 |
| Mellon Capital Management Corporation | 755375 | 1.25% | -102133 | -11.91% | 2018-06-30 |
| Cadian Capital Management, LLC | 725092 | 1.20% | -486497 | -40.15% | 2018-06-30 |
| Teachers Advisors Inc | 686192 | 1.14% | 27936 | 4.24% | 2018-06-30 |
| FIL Investment Services (UK) Ltd | 645460 | 1.07% | -28 | -- | 2018-05-31 |
| Janus Capital Management LLC | 743804 | 1.24% | -8379 | -1.11% | 2018-03-31 |
| Goldman, Sachs & Co. | 694095 | 1.09% | 146949 | 26.86% | 2017-12-31 |
| Pioneer Investment Mgmt Inc | 891322 | 1.48% | 54895 | 6.56% | 2017-09-30 |
| Citadel Advisors Llc | 650923 | 1.08% | 153361 | 30.82% | 2017-09-30 |
| American Century Inv Mgt Inc | 631764 | 1.05% | 81864 | 14.89% | 2017-09-30 |
| Quantitative Management Associates LLC | 546738 | 0.90% | -63849 | -10.46% | 2016-09-30 |
| Swedbank Robur Fonder AB | 525549 | 0.88% | 1300 | 0.25% | 2017-01-31 |
| Boston Co Asset Management LLC | 523544 | 0.86% | -29899 | -5.40% | 2016-09-30 |
| Two Sigma Investments LLC | 520201 | 0.86% | 58824 | 12.75% | 2016-09-30 |
| The Vanguard Group | 3477267 | 5.00% | 618988299 | 0.10% | 1999-11-30 |
| BlackRock, Inc. | 3692629 | 5.00% | 657324888 | 0.10% | 1999-11-30 |
| Putnam Investment, LLC | 7926631 | 5.00% | 1411019584 | 0.10% | 1999-11-30 |
| FMR LLC | 9091136 | 5.00% | 1618313119 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Janus Henderson Global Life Sciences Fd | 255547 | 0.45% | -9441 | -3.56% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1549931 | 2.74% | -33928 | -2.14% | 2019-06-30 |
| Vanguard Mid-Cap Index Fund | 1311341 | 2.32% | -65829 | -4.78% | 2019-06-30 |
| CREF Stock Account | 781419 | 1.38% | 76839 | 10.91% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 778092 | 1.37% | -11532 | -1.46% | 2019-06-30 |
| Putnam Capital Spectrum Fund | 673248 | 1.19% | -35600 | -5.02% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 559332 | 0.99% | 5840 | 1.06% | 2019-07-30 |
| Fidelity America Fund | 498431 | 0.88% | -12 | -- | 2019-06-30 |
| JPMorgan Growth Advantage Fund | 483800 | 0.85% | -- | -- | 2019-06-30 |
| JHancock Disciplined Value Mid Cap Fund | 467325 | 0.83% | 16863 | 3.74% | 2019-05-31 |
| Fidelity | 262200 | 0.46% | -- | -- | 2019-06-30 |
| SEB L | 263600 | 0.47% | 66200 | 33.54% | 2019-06-30 |
| Franklin Biotechnology Discovery Fund | 308231 | 0.54% | 12200 | 4.12% | 2019-06-30 |
| Vanguard Mid-Cap Growth Index Fund | 342872 | 0.61% | -7589 | -2.17% | 2019-06-30 |
| JPMorgan Mid Cap Growth Fund | 348770 | 0.62% | 18000 | 5.44% | 2019-06-30 |
| Putnam Equity Spectrum Fund | 372269 | 0.66% | -20000 | -5.10% | 2019-06-30 |
| Vanguard Growth Index Fund | 384656 | 0.68% | -11810 | -2.98% | 2019-06-30 |
| CREF Growth Account | 425611 | 0.75% | -259161 | -37.85% | 2019-04-30 |
| TIAA-CREF Large-Cap Growth Fund | 305335 | 0.54% | -7278 | -2.33% | 2019-03-31 |
| Putnam Global Health Care Fund | 364400 | 0.64% | 23500 | 6.89% | 2018-12-31 |
| Carillon Scout Mid Cap Fund | 311450 | 0.55% | 311450 | -- | 2018-12-31 |
| CLI Fidelity American | 566833 | 0.99% | -11 | -- | 2019-01-31 |
| American Century Heritage Fund | 368023 | 0.61% | 58408 | 18.86% | 2018-09-30 |
| AZ InvestEd Ivy Mid Cap Growth Fund | 295911 | 0.49% | -- | -- | 2018-09-30 |
| Vanguard Mid Cap Index I | 1352918 | 2.24% | 10824 | 0.81% | 2018-07-31 |
| Vanguard Mid-Cap Growth ETF | 345729 | 0.57% | 1554 | 0.45% | 2018-07-31 |
| JPMorgan Mid Cap Growth Sel | 365970 | 0.61% | 12700 | 3.59% | 2018-07-31 |
| Fidelity VIP Mid Cap Inv | 376071 | 0.62% | -- | -- | 2018-07-31 |
| Putnam Global Health Care A | 402600 | 0.67% | -61500 | -13.25% | 2018-06-30 |
| Vanguard Growth Index Inv | 401454 | 0.66% | -1140 | -0.28% | 2018-07-31 |
| Putnam Capital Spectrum A | 2842521 | 4.72% | -1775756 | -38.45% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 1432632 | 2.37% | 1380 | 0.10% | 2018-07-31 |
| Putnam Equity Spectrum A | 1068954 | 1.77% | -305582 | -22.23% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 794735 | 1.32% | 2400 | 0.30% | 2018-07-31 |
| CREF Stock R1 | 675188 | 1.12% | 33773 | 5.27% | 2018-07-31 |
| iShares Nasdaq Biotechnology | 680691 | 1.09% | -1296 | -0.19% | 2018-09-12 |
| CREF Growth R1 | 520774 | 0.86% | -45788 | -8.08% | 2018-07-31 |
| JPMorgan Growth Advantage A | 485200 | 0.80% | 3400 | 0.71% | 2018-07-31 |
| JHancock Disciplined Value Mid Cap A | 265166 | 0.44% | 5006 | 1.92% | 2018-05-31 |
| TIAA-CREF Large-Cap Growth Inst | 309332 | 0.52% | -3144 | -1.01% | 2018-05-31 |
| American Century Heritage Inv | 309615 | 0.51% | 65072 | 26.61% | 2018-06-30 |
| AZ InvestEd Ivy Mid Cap Growth E | 295911 | 0.49% | 135959 | 85.00% | 2018-03-31 |
| Fidelity Spartan | 264208 | 0.44% | -- | -- | 2018-05-31 |
| Fidelity VIP Contrafund Inv | 364400 | 0.61% | -11000 | -2.93% | 2018-04-30 |
| Janus Global Life Sciences D | 293077 | 0.49% | -8379 | -2.78% | 2018-03-31 |
| Janus D | 294209 | 0.49% | -- | -- | 2017-03-31 |
| Pioneer Mid Cap Value A | 287903 | 0.45% | -31950 | -9.99% | 2018-01-31 |
| Dreyfus Opportunistic Midcap Value A | 314158 | 0.52% | 14111 | 4.70% | 2016-12-31 |
| Fidelity® Capital Appreciation Fund | 1094010 | 1.80% | -- | -- | 2015-10-31 |
| Putnam Voyager Fund | 897400 | 1.50% | 170177 | 23.40% | 2015-09-30 |
| Fidelity® Select Health Care Portfolio | 840000 | 1.40% | -160000 | -16.00% | 2015-10-31 |
| Generali Worldwide Fidelity Amer | 667395 | 1.10% | 18 | -- | 2015-10-31 |
| JOHCM International Select Fund | 588500 | 1.00% | 16645 | 2.90% | 2015-07-31 |
| JOHCM Global Select | 548117 | 0.90% | -35780 | -6.10% | 2015-08-31 |
| Fidelity® Value Fund | 509167 | 0.80% | 23100 | 4.80% | 2015-10-31 |
| Fidelity® Growth Company Fund | 502400 | 0.80% | -- | -- | 2015-10-31 |
| Fidelity® Select Biotechnology Portfolio | 1462954 | 2.40% | 152534 | 11.60% | 2015-10-31 |
| Michael Patrick Miller | Michael Patrick Miller is on the board of The Leukemia & Lymphoma Society, Inc., Puma Biotechnology, Inc. and Zane Beadles Parade Foundation and Executive Vice President-Commercial at Jazz Pharmaceuticals Plc. He previously held the position of Chief Commercial Officer & Senior Vice President at VIVUS, Inc., Vice President-Commercial Operations at Cellegy Pharmaceuticals, Inc., Vice President at ALZA Corp., Senior Vice President-Sales & Marketing at Connetics Corp. and Vice President-Sales & Marketing for Genentech, Inc. He received an undergraduate degree from the University of San Francisco and an MBA from San Francisco State University. |
|---|---|
| Bruce C. Cozadd | Bruce C. Cozadd is a businessperson who founded Jazz Pharmaceuticals Plc and Jazz Pharmaceuticals, Inc. and who has been the head of 5 different companies. Currently, Mr. Cozadd is Chairman at The Nueva School and Chairman & Chief Executive Officer for Jazz Pharmaceuticals Plc, Chairman & Chief Executive Officer for Jazz Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc). Bruce C. Cozadd is also on the board of Pharmaceutical Research & Manufacturers of America and SFJAZZ. Mr. Cozadd previously occupied the position of Chairman & Chief Executive Officer at Azur Pharma Ltd., President & Director at Celator Pharmaceuticals, Inc., Chief Operating Officer & Executive Vice President at ALZA Corp., Member of Harris Upham & Co, Inc. and Member-Health Care Investment Banking Team at Smith Barney Harris Upham & Co., Inc. He received an undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business. |
| Norbert G. Riedel | Founder of Aptinyx, Inc., Norbert G. Riedel currently is President, Chief Executive Officer & Director at this company. Dr. Riedel is also Member of Osterreichische Akademie Der Wissenschaften and on the board of 6 other companies. In his past career Dr. Riedel held the position of Chief Scientific & Innovation Officer at Baxter International, Inc. and President-Recombinant Strategic Business Unit at Baxter BioScience Corp. (a subsidiary of Baxter International, Inc.), Member of Austrian Academy of Sciences, President, Chief Executive Officer & Director at Naurex, Inc., Head-Global Biotechnology at Hoechst Marion Roussel, Inc., Principal at Hoechst AG and Associate Professor at Boston University School of Medicine. Dr. Riedel received a doctorate and an undergraduate degree from Johann Wolfgang Goethe-Universit�0�1¤t Frankfurt am Main. |
| Patrick G. Enright | Patrick G. Enright founded Longitude Capital Management Co. LLC. Presently, Mr. Enright is Managing Director at this company. He is also on the board of 10 other companies. In the past he held the position of Managing Director at FirstMark Capital LLC, Chief Financial Officer & Senior Vice President of Urigen Pharmaceuticals, Inc. and Chief Financial Officer & SVP-Business Development at Valentis, Inc. (a subsidiary of Urigen Pharmaceuticals, Inc.), Senior VP-Finance & Business Development at Boehringer Mannheim Pharmaceuticals Corp., Managing Member at Delta Opportunity Fund LLC, Principal at Sandoz, Inc. and Vice President at PaineWebber Development Corp. Patrick G. Enright received an undergraduate degree from Stanford University and an MBA from The Wharton School of the University of Pennsylvania. |
| Peter Gray | Currently, Peter Gray is Chairman at Teckro Ltd. and Chairman for UDG Healthcare Plc. He is also on the board of Jazz Pharmaceuticals Plc. In the past he occupied the position of Vice Chairman & Chief Executive Officer for ICON plc. Mr. Gray received a graduate degree from Trinity College Dublin. |
| Paul L. Berns | Paul L. Berns is a businessperson who has been the head of 5 different companies. Currently, Mr. Berns occupies the position of Executive Chairman at Blackthorn Therapeutics, Inc. Mr. Berns is also on the board of Menlo Therapeutics, Inc., Jazz Pharmaceuticals Plc, Unity Biotechnology, Inc. and Mc2 Therapeutics AS. In the past he held the position of Chairman at Cellectar BioSciences, Inc., General Manager-Immunology & Oncology at Abbott Laboratories, Chairman, President & Chief Executive Officer of Anacor Pharmaceuticals, Inc., President & Chief Executive Officer at Bone Care International, Inc., President, Chief Executive Officer & Director at Allos Therapeutics, Inc., Vice President-Marketing at Knoll AG and Vice President-Marketing at BASF SA. Mr. Berns received an undergraduate degree from the University of Wisconsin. |
| Karen J. Wilson | Karen J. Wilson occupies the position of Chief Accounting Officer & SVP-Finance at Jazz Pharmaceuticals Plc. In her past career she held the position of Chief Accounting Officer & Vice President-Finance at PDL BioPharma, Inc., Principal at Wilson Crisler LLC, Chief Financial Officer & VP-Operations at Novare Surgical Systems, Inc., Chief Financial Officer for Monogram Biosciences, Inc., Senior Manager at Deloitte & Touche LLP, Chief Accounting Officer & Vice President for Azur Pharma Ltd. and Chief Accounting Officer & Vice President-Finance at Jazz Pharmaceuticals, Inc. Ms. Wilson received an undergraduate degree from the University of California, Berkeley. |
| Craig C. Parker | Founder of Vega Therapeutics, Inc., Craig C. Parker is Chief Executive Officer & Director at Surrozen, Inc. He is also on the board of vTv Therapeutics, Inc. and Senior VP & Head-Corporate Development at Jazz Pharmaceuticals Plc. In the past Mr. Parker held the position of Chief Executive Officer for Vega Therapeutics, Inc., EVP-Corporate Development & Scientific Affairs at Geron Corp., Chief Financial Officer of Proteolix, Inc., Senior VP-Strategy & Corporate Development at Human Genome Sciences, Inc., Senior Vice President & General Manager at Immunex Corp. and Managing Director at Lehman Brothers, Inc. Mr. Parker received an undergraduate degree from The University of Chicago and an MBA from Stephen M. Ross School of Business. |
| Ken W. O'Keefe | Mr. Ken W. O'Keefe is an Independent Director at Jazz Pharmaceuticals Plc and a Managing Director at Beecken Petty O'Keefe & Co. LP. He is on the Board of Directors at Jazz Pharmaceuticals Plc. Mr. O'Keefe was previously employed as an Independent Director by Jazz Pharmaceuticals, Inc., a Managing Director by First Chicago Corp., and a Principal by Smith Barney, Inc. He also served on the board at PerfectServe, Inc. He received his undergraduate degree from Northwestern University and an MBA from The University of Chicago. |
| Rick E. Winningham | Rick E. Winningham is a businessperson who has been the head of 6 different companies. He holds the position of Chairman & Chief Executive Officer for Theravance Biopharma, Inc. and Chief Executive Officer of Theravance Biopharma US, Inc. (a subsidiary of Theravance Biopharma, Inc.). Mr. Winningham is also on the board of Biotechnology Innovation Organization, Jazz Pharmaceuticals Plc and California Biomedical Innovation Alliance (former Chairman). In the past he occupied the position of Chairman for Innoviva, Inc., President-Global Marketing at Bristol-Myers Squibb Co., Chairman of California Healthcare Institute and Chairman for California Life Sciences Association. Rick E. Winningham received an MBA from Texas Christian University and an undergraduate degree from Southern Illinois University. |
| Daniel N. Swisher | Daniel N. Swisher is Chairman of Cerus Corp. and President & Chief Operating Officer of Jazz Pharmaceuticals Plc. He is also on the board of Corcept Therapeutics, Inc. and The Okizu Foundation. He previously was President, CEO, Secretary & Director at Sunesis Pharmaceuticals, Inc. and Senior Vice President-Sales & Marketing for ALZA Corp. He received an undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business. |
| Katherine A. Littrell | Katherine A. Littrell occupies the position of Vice President-Investor Relations at Jazz Pharmaceuticals Plc. Dr. Littrell previously held the position of Vice President-Investor Relations for Genentech, Inc. |
| Suzanne Sawochka Hooper | Suzanne Sawochka Hooper is Executive Vice President & General Counsel at Jazz Pharmaceuticals Plc and Secretary, Executive VP & General Counsel at Jazz Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc). Ms. Hooper is also on the board of NGM Biopharmaceuticals, Inc. and Member of American Bar Association and Member of The State Bar of California. In the past Ms. Hooper held the position of Partner at Cooley LLP and Secretary at Celator Pharmaceuticals, Inc. Suzanne Sawochka Hooper received an undergraduate degree from the University of California, Santa Barbara and a graduate degree from Berkeley Law University of California. |
| Elmar J. Schnee | Elmar J. Schnee is a Swiss businessperson who has been at the head of 8 different companies and occupies the position of Chairman of Santhera Pharmaceuticals Holding AG, Chairman for Calliditas Therapeutics AB, Chairman at Noorik Biopharmaceuticals AG, Chairman at Procom RX, Non-Executive Chairman at Moleac Pte Ltd. and Secretary at MindMaze SA. Dr. Schnee is also on the board of Jazz Pharmaceuticals Plc, Stallergenes Greer Plc and Damien AG. In the past Dr. Schnee held the position of Non-Executive Director at Cardiorentis AG, Member-Executive Board & General Partner at Merck KGaA Managing Director at Merck Sant�0�1�0�8 SAS and President of Merck Serono SA (both are subsidiaries of Merck KGaA), Managing Director at Migliara Kaplan & Associates, Managing Director at Fisons Plc, Managing Director at Sanofi-Synth�0�1�0�8labo Ltd. and Managing Director at UCB Pharma Ltd. Dr. Schnee received an undergraduate degree from Schweizerisches Institut f�0�1�0�4r Betriebs�0�1�0�9konomie AG. |
| Seamus C. Mulligan | Seamus C. Mulligan founded Azur Pharma Ltd. Mr. Mulligan is on the board of Emergent BioSolutions, Inc. and Jazz Pharmaceuticals Plc. In his past career he occupied the position of Executive Chairman for Circ Pharma Ltd., Chairman & Chief Executive Officer at Azur Pharma Ltd., Chairman & Chief Executive Officer for Adapt Pharma Ltd. and Vice President-Business & Corporate Development at Elan Corp. Plc. He received a graduate degree and an undergraduate degree from Trinity College Dublin. |
| Heather Ann McSharry | Ms. Heather A. McSharry is an Independent Director at Jazz Pharmaceuticals Plc, an Independent Non-Executive Director at Greencore Group Plc and an Independent Non-Executive Director at CRH Plc. She is on the Board of Directors at Uniphar Plc, Jazz Pharmaceuticals Plc, Greencore Group Plc, CRH Plc, Ergonomic Solutions International Ltd., Institute of Directors In Ireland and Ergonomic Solutions Ltd. Ms. McSharry was previously employed as a Non-Executive Director by Bank of Ireland, a Managing Director-Ireland Region by Reckitt Benckiser Ireland Ltd., and a Managing Director by Boots Healthcare International Ltd. She also served on the board at Industrial Development Authority of Ireland. She received her undergraduate degree from the University College Dublin and a graduate degree from the University College Dublin. |
| Rick E. Winningham | Rick E. Winningham is a businessperson who has been the head of 6 different companies. He holds the position of Chairman & Chief Executive Officer for Theravance Biopharma, Inc. and Chief Executive Officer of Theravance Biopharma US, Inc. (a subsidiary of Theravance Biopharma, Inc.). Mr. Winningham is also on the board of Biotechnology Innovation Organization, Jazz Pharmaceuticals Plc and California Biomedical Innovation Alliance (former Chairman). In the past he occupied the position of Chairman for Innoviva, Inc., President-Global Marketing at Bristol-Myers Squibb Co., Chairman of California Healthcare Institute and Chairman for California Life Sciences Association. Rick E. Winningham received an MBA from Texas Christian University and an undergraduate degree from Southern Illinois University. |
| Iain Robert McGill | Iain Robert McGill is on the board of Otonomy, Inc. and Senior Vice President-Jazz Pharmaceuticals Europe at Jazz Pharmaceuticals Plc. In the past he was Chief Commercial Officer for Eusa Pharma Europe Ltd., Chief Commercial Officer at EUSA Pharma, Inc., Chief Commercial Officer of Jazz Pharmaceuticals UK Ltd. and Vice President for Wyeth Corp. He received an undergraduate degree from the University of London. |
| Paul Treacy | Currently, Paul Treacy holds the position of Senior Vice President-Technical Operations at Jazz Pharmaceuticals Plc. Mr. Treacy previously occupied the position of General Manager at Janssen Biologics (Ireland), Head-CMC, Supply Chain & Manufacturing at Janssen Alzheimer Immunotherapy Research & Development LLC and Vice President-Manufacturing Operations at Centocor, Inc. He received an undergraduate degree from University College Cork. |
| Russell J. Cox | Mr. Russell J. Cox is Chief Operating Officer & Executive Vice President at Jazz Pharmaceuticals Plc and Chief Operating Officer & EVP at Jazz Pharmaceuticals, Inc. He is on the Board of Directors at Aeglea Biotherapeutics, Inc. and Vascular Cures. Mr. Cox was previously employed as Senior Vice President & Chief Commercial Officer by Ipsen, Inc., Vice President-Marketing by Tercica, Inc., Vice President-Marketing by Scios, Inc., and Product Team Leader by Genentech, Inc. He received his undergraduate degree from Texas A&M University. |
| Robert McKague | Currently, Robert McKague holds the position of Chief Compliance Officer & Senior Vice President at Jazz Pharmaceuticals Plc and CCO, SVP & Associate General Counsel at Jazz Pharmaceuticals, Inc. (a subsidiary of Jazz Pharmaceuticals Plc). In his past career Mr. McKague occupied the position of Litigation Associate at Morrison & Foerster LLP, Senior Corporate Counsel at Oracle America, Inc. and Senior Counsel at Actelion Pharmaceuticals US, Inc. He received a graduate degree from the University of California, Hastings and an undergraduate degree from San Francisco State University. |
| Catherine Angell Sohn | Dr. Catherine A. Sohn is an Independent Director at Landec Corp., an Independent Director at Jazz Pharmaceuticals Plc, a President at Sohn Health Strategies LLC, a Non-Executive Chairman at BioEclipse Therapeutics, Inc. and a Professor at University of the Sciences in Philadelphia. She is on the Board of Directors at Rubius Therapeutics, Inc., Landec Corp., Jazz Pharmaceuticals Plc, Dohmen Co., Ariel Pharmaceuticals, Inc., Eversana Life Science Services LLC and World Affairs Council of Philadelphia. Dr. Sohn was previously employed as an Independent Director by Neuralstem, Inc., a Trustee by Licensing Executives Society USA & Canada, Inc., a Senior Vice President-Business Development by Glaxosmithkline Consumer Healthcare LP, a Senior VP-Worldwide Business Development by GlaxoSmithKline Plc, an Assistant Professor by Philadelphia College of Pharmacy, a Senior Vice President-Worldwide Business by GlaxoSmithKline LLC, and a VP-Worldwide Strategic Product Development by Smithkline Beecham Pharmaceuticals Ltd. She also served on the board at CHD Bioscience, Inc., Consumer Healthcare Products Association, Healthcare Businesswomens Association and World Self-Medication Industry Association. She received her doctorate degree from The University of California, San Francisco. |
| Jacqueline Pomfret Kirby | Currently, Jacqueline Pomfret Kirby holds the position of VP-Corporate Affairs & Government Relations at Jazz Pharmaceuticals Plc and Vice President-Government Affairs at AstraZeneca Pharmaceuticals LP. |
| Patricia Carr | Patricia Carr is Vice President-Finance for Jazz Pharmaceuticals Plc. |
| Matthew P. Young | Matthew P. Young is on the board of PRA Health Sciences, Inc. and CytomX Therapeutics, Inc. and Chief Financial Officer & Executive Vice President of Jazz Pharmaceuticals Plc. He previously was Managing Director at Citigroup Global Markets, Inc., Managing Director at Lehman Brothers, Inc., Managing Director-Global Healthcare at Barclays Capital, Inc. and Treasurer & Director at Celator Pharmaceuticals, Inc. Matthew P. Young received an MBA and an undergraduate degree from The Wharton School of the University of Pennsylvania. |
| Karen L. Smith | Dr. Karen L. Smith is an Independent Director at Acceleron Pharma, Inc. and a Chief Medical Officer & EVP-Research & Development at Jazz Pharmaceuticals Plc. She is on the Board of Directors at Acceleron Pharma, Inc. and Sucampo Pharmaceuticals, Inc. Dr. Smith was previously employed as a Director & Vice President by Celator Pharmaceuticals, Inc., a Non-Executive Director by Forward Pharma A/S, a Senior Vice President-Global Medical Affairs by Allergan, Inc., a Vice President-Global Development by AstraZeneca LP, a Head-US Clinical Operations by Bristol-Myers Squibb Co., and a Chief Executive Officer by Boron Molecular Ltd. She received her undergraduate degree from Curtin University, a graduate degree from the University of Salford, an MBA from the University of New England (Australia), a doctorate degree from the University of Warwick and a doctorate degree from The University of Western Australia. |
| Robert Iannone | Currently, Robert Iannone is Executive Vice President-Research & Development at Jazz Pharmaceuticals Plc. In the past Dr. Iannone occupied the position of Chief Medical Officer, Head-Research & Development at Immunomedics, Inc. and SVP & Head-Immuno-Oncology, Global Medicines at AstraZeneca Plc. Dr. Iannone received a graduate degree from the University of Pennsylvania Medical Center and a doctorate from Yale School of Medicine. |
| Paul Treacy | Currently, Paul Treacy holds the position of Senior Vice President-Technical Operations at Jazz Pharmaceuticals Plc. Mr. Treacy previously occupied the position of General Manager at Janssen Biologics (Ireland), Head-CMC, Supply Chain & Manufacturing at Janssen Alzheimer Immunotherapy Research & Development LLC and Vice President-Manufacturing Operations at Centocor, Inc. He received an undergraduate degree from University College Cork. |
| Allen Yang | Allen Yang is VP & Therapeutic Area Head-Hematology/Oncology at Jazz Pharmaceuticals Plc. |
| Aislinn Doody | Presently, Aislinn Doody occupies the position of Secretary for Jazz Pharmaceuticals Plc. |
| Lawrence Carter | Lawrence Carter is Senior Director-Clinical Development Sleep at Jazz Pharmaceuticals Plc. |
| Anne O'Riordan | Anne O'Riordan is on the board of Hongkong Land Co Ltd., American Chamber of Commerce and Jazz Pharmaceuticals Plc and Member of The Womens Foundation, Senior Managing Director at Accenture Life Sciences Pvt Ltd. and Senior Managing Director at Accenture LLC. Mr. O'Riordan received an undergraduate degree from Dublin City University and a graduate degree from National University of Ireland Galway. |
| Heidi Manna | Presently, Heidi Manna is Chief Human Resources Officer & SVP at Jazz Pharmaceuticals Plc. Ms. Manna previously held the position of Vice President-Human Resources of Campbell Soup Co. She received an undergraduate degree from State University of New York at Binghamton and an MBA from State University of New York at Buffalo. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论